Biofrontera BFRI
NASDAQ BFRI
$0.79 +0.01 (+1.28%)
At close: Oct 23, 2026 · 4:00 PM EDT

Biofrontera (BFRI) Sale and Maturity of Investments (2023 - 2024)

Updated

Analysis

Biofrontera (BFRI) Sale and Maturity of Investments (2023 - 2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Investments Sold (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn -
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn 308.00 Mn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn -
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn 1.30 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn 136.00 Mn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn -
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn -
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn 1.03 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn 2.12 Bn
10 Biofrontera 11.22 Mn -10.57 Mn 9.59 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 57,000.00
Dec 31, 2023 64,000.00
Sep 30, 2023 360,000.00
API Access

Biofrontera Sale and Maturity of Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=sale-and-maturity-of-investments&ticker=BFRI&period=max&api_key=YOUR_API_KEY